<DOC>
	<DOC>NCT00727129</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.</brief_summary>
	<brief_title>Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal women Have moderate to severe hot flashes Normal Pap Smear Abnormal mammogram Abnormal clinical breast exam BMI &gt;35</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>vasomotor symptoms</keyword>
	<keyword>estrogen</keyword>
	<keyword>estradiol</keyword>
	<keyword>hot flashes</keyword>
</DOC>